Strona 5 - Najlepsi lekarze wykonujący chemioterapię – TOP 152 lekarzy

Dr Tabernero został uznany przez magazyn Forbes za jednego z 5 najbardziej wpływowych liderów w dziedzinie onkologii w Hiszpanii. Były prezydent Europejskiego Towarzystwa Onkologii Klinicznej (European Society for Medical Oncology).

• Dyrektor Instytutu Onkologii Vall d’Hebrón
• Specjalizuje się w molekularnych terapiach celowanych i spersonalizowanym leczeniu raka
• Autor ponad 70 prac naukowych na temat innowacyjnych metod leczenia raka
• Prowadzi badania kliniczne nowych terapii raka jelita grubego

Dr Alemdar specjalizuje się w onkologii medycznej, z rozległym szkoleniem na Uniwersytecie Akdeniz – wiodącej instytucji w Turcji.

• Certyfikowany w onkologii medycznej od 2018 roku
• Ponad 15 lat doświadczenia w chorobach wewnętrznych i onkologii
• Pracuje w Kompleksie Szpitalnym Medical Park Antalya
• Członek Tureckiego Stowarzyszenia Medycznego

Docent Tarik Salman specjalizuje się w spersonalizowanym leczeniu nowotworów w Szpitalu Międzynarodowym Medicalpoint, w tym w kompleksowym profilowaniu genomowym.

• Ponad 15 lat doświadczenia w onkologii klinicznej
• Szkolił się w Memorial Sloan Kettering Cancer Center
• Członek zarządu wielu stowarzyszeń onkologicznych
• Ekspert w dziedzinie terapii celowanych i immunoterapii

Assoc. Prof. Ayşe İrem Yasin, M.D., is a medical oncologist who specializes in solid tumors. Her clinical focus includes breast, lung, gastrointestinal, gynecologic, and urologic cancers. She also treats brain and other CNS tumors, soft tissue sarcomas, head and neck cancers, adenocarcinomas, melanoma, Merkel cell carcinoma, and cancers of unknown primary. She practices at Medipol Acıbadem District Hospital (2025–present). She previously worked at Şişli Etfal Training and Research Hospital (2023–2025).

She completed a Medical Oncology fellowship at Bezmialem Vakıf University (2019–2022). This followed an Internal Medicine residency at the same institution (2012–2016). Her international experience includes the Breast Cancer Unit at the University of Piemonte Orientale in Novara (2022). She also trained at Basel University Hospital, Cleveland Clinic, and Harvard Medical School. She holds the ESMO Board Certificate (2022).

Assoc. Prof. Dr. Mehmet Salih İyikesici is a medical oncologist. He provides personalized care for breast, lung, and gastrointestinal cancers. He combines metabolically supported therapies with chemotherapy. His interests include the ketogenic diet in cancer care, hyperthermia, and hyperbaric oxygen therapy.

He has conducted and contributed to national and international scientific studies. Selected national peer-reviewed publications include Metabolic Supported Chemotherapy in Rectal Cancer (2020), NSCLC Patient Outcomes – Marmara University (2004), and Early-Stage Breast Cancer Outcomes (2004).

Prof. Avichai Shimoni, MD, is Director of Bone Marrow Transplantation at Sheba Medical Center. He is a hemato-oncologist with over 30 years of experience in bone marrow transplantation, cellular therapies, and advanced blood cancer care.

He leads a high-volume program for complex, high-risk blood cancers. He performs allogeneic and autologous transplants. He also provides CAR T-cell therapy for leukemia, lymphoma, and multiple myeloma. He completed a bone marrow transplantation fellowship at MD Anderson Cancer Center.

He is Chairman of Hematology at Tel Aviv University and a Professor of Hematology. He has authored more than 250 scientific papers. His research focuses on CAR T-cell therapy and stem cell transplantation. He is often listed among Israel's Best Doctors (Forbes 2025 and 2026).

Dr. Lucía González Cortijo is a medical oncologist with more than 20 years of experience. She has led the Medical Oncology Department at Hospital Universitario Quirónsalud Madrid since 2020. Her focus areas include breast and gynecologic cancers. She also works in precision oncology, targeted therapies, and immunotherapy.

She has been Principal Investigator in more than 20 Phase II–III clinical trials. She has also served as sub-investigator in over 50 international trials. She previously worked at Quirónsalud Madrid from 2009 to 2020. Before that, she was at MD Anderson Cancer Center Madrid from 2002 to 2009.

She holds an MD and a PhD (cum laude) from the Autonomous University of Madrid. She completed her Medical Oncology specialty training at Hospital 12 de Octubre. She also earned a Master’s in Molecular Oncology. She is a member of SEOM, ESMO, ASCO, and GEICAM. She is a university lecturer.

Prof. Ben Boursi is a physician in the Gastrointestinal Cancer Department at Sheba Medical Center. He specializes in internal medicine, medical oncology, and cancer epidemiology. He is board certified in internal medicine and medical oncology. He earned a B.Med.Sc (summa cum laude) and an MD (magna cum laude) from Tel Aviv University.

He completed clinical and research fellowships in GI oncology and cancer epidemiology at the University of Pennsylvania. He also completed electives at MD Anderson and Mayo Clinic. He founded the ECOG-ACRIN Microbiome Working Group. His microbiome-oncology research has been published in leading journals, including Science, and highlighted by ASCO.

He developed predictive models for early diagnosis of colorectal and pancreatic cancers. These models are now in clinical evaluation. He holds an academic appointment at Tel Aviv University. He is also an Associate Scholar at the University of Pennsylvania.

Dr. Abraham Avigdor, MD, is Director of the Institute of Hematology and Co‑Director of the Hematology & Bone Marrow Transplantation Division at Sheba Medical Center. He is an international leader in lymphoma, CAR‑T, and advanced hemato‑oncology with more than 35 years of experience. His clinical focus includes lymphomas, multiple myeloma, and complex blood cancers.

He is a pioneer in CAR‑T integration. He leads cellular therapy and bone marrow transplantation programs (autologous and allogeneic). He also advances stem cell therapies and precision diagnostics, including PET/CT‑based prognostics. His work includes immunotherapy and targeted regimens and the development of innovative, data‑driven protocols.

He collaborates with LYSA, EMCL, and international PET groups. He has authored more than 130 publications. Key roles include Founder and President of the Israeli Lymphoma Working Group, former Chair of the Israeli Lymphoma Study Group, and Senior Lecturer at Tel Aviv University. Education: MD, Ben‑Gurion University; residency, Sheba Medical Center; postdoctoral fellowship, Weizmann Institute. Awards include the Knesset Prize, the Israeli Ministry of Health Award, and the Sackler Prize.

Profesor nadzwyczajny Muhammed Mustafa Atci kieruje programem Onkologii Klinicznej w Istinye University Liv Hospital Topkapı, prowadząc szeroko zakrojone badania nad wynikami chemioterapii.

• Specjalizuje się w onkologii klinicznej, koncentrując się na protokołach chemioterapii
• Opublikował liczne badania dotyczące skuteczności chemioterapii w recenzowanych czasopismach
• Jest członkiem Amerykańskiego Towarzystwa Onkologii Klinicznej (ASCO)
• Koordynator ds. edukacji Pododdziału Onkologii Medycznej

Professor Raanan Berger, MD PhD, is a medical oncologist and radiotherapist. He is Director of the Cancer Center at Sheba Medical Center and heads its clinical research unit. He was listed in Forbes Israel’s “Best Doctors” (2025). He leads the genitourinary oncology program with a focus on prostate cancer. His care includes systemic therapy and radiotherapy in a multidisciplinary, patient-centered model.

He is board-certified in oncology. He earned his MD and PhD at Tel Aviv University and completed his clinical training at Sheba. He then completed a postdoctoral fellowship at Dana-Farber/Harvard, focusing on prostate cancer with Dr. Philip Kantoff and molecular oncology in Dr. William C. Hahn’s lab. He is a member of ESMO and ASCO. He has co-authored more than 20 peer-reviewed papers, including studies on outcomes in high- versus very high-risk prostate cancer and on BRCA1/2 in large cohorts.

Dyrektor kliniczny interdyscyplinarnego ośrodka chorób piersi z 322 recenzowanymi publikacjami – dr Kuemmel kieruje badaniami nad rakiem piersi w Kliniken Essen-Mitte.

• Członek Zarządu AGO (Arbeitsgemeinschaft Gynäkologische Onkologie)
• Członek wydziału ESMO ds. raka piersi
• Globalny główny badacz (PI) i kierownik 27 badań klinicznych
• Członek wielu prestiżowych towarzystw onkologicznych, w tym ESMO i ASCO

Professor Jair Bar, MD, PhD, is a thoracic oncologist and Deputy Director of the Cancer Center at Sheba Medical Center. He leads the Thoracic Oncology Unit. He treats lung cancer, including advanced non-small cell cases. His care includes medical oncology, radiotherapy, immunotherapy, and targeted therapy.

He runs a translational research lab focused on resistance to immunotherapy. He has published on exhaled-breath cancer metabolism and on angiogenesis inhibition in lung cancer.

He has chaired the Israel Lung Cancer Group since 2003. He is a member of the Israel Society of Clinical Oncology and Radiotherapy, the American Society of Clinical Oncology, and the American Association for Cancer Research. He is board-certified in Medical Oncology and Radiotherapy Oncology. He is a Senior Lecturer at Tel Aviv University.

Dr. Hila Magen, MD, leads the Multiple Myeloma and Amyloidosis Unit at Sheba Medical Center. She is a hemato-oncologist with over 35 years of experience. She is a leading Israeli expert in multiple myeloma and plasma cell disorders.

She runs a program that provides personalized care and early access to clinical trials. This includes CAR-T therapy for high-risk and relapsed or refractory myeloma and amyloidosis. Dr. Magen is a principal investigator in point-of-care CAR-T studies. She brings new immunotherapies into routine care.

Training: Fellowships in Multiple Myeloma (UAMS) and Lymphocytic Leukemia (MD Anderson). Academic: Instructor, Tel Aviv University. Research: Author of 100+ publications, contributor to landmark myeloma studies, and reviewer for international journals.

Wiodący ekspert w dziedzinie przewlekłej białaczki limfocytowej (PBL) – Profesor Bosch był pionierem nowych metod leczenia i technologii w chorobach hematologicznych.

• Prowadzi ponad 80 badań klinicznych (od fazy 1 do fazy 3)
• Opublikował ponad 100 artykułów w najlepszych czasopismach medycznych
• Kierownik Hematologii w Instytucie Onkologii IOB
• Prezes Hiszpańskiej Grupy Badawczej PBL (GELLC)

Główny badacz w badaniach klinicznych nad rakiem jajnika, szyjki macicy i endometrium – dr Oaknin prowadzi przełomowe badania w Hospital Quirón Barcelona.

• Autor ponad 100 publikacji na temat nowotworów ginekologicznych
• Członek zarządu Grupy GEICO (Hiszpańska Grupa Badawcza Raka Jajnika)
• Członek wydziału Gyn-Track w ESMO
• Reprezentant Hiszpanii w Komitecie Szyjki Macicy Grupy GCIG

Wiodący izraelski specjalista w dziedzinie immunoterapii raka płuc – prof. Peled kieruje Oddziałem Onkologii Klatki Piersiowej (Torakalnej) w Centrum Onkologicznym Davidoff.

• Odbył szkolenie (fellowship) z zakresu raka płuc na Uniwersytecie Kolorado w Denver
• Laureat nagrody MERIT przyznanej przez Amerykańskie Towarzystwo Onkologii Klinicznej (ASCO)
• Przewodniczy Komitetowi Wczesnego Wykrywania i Prewencji Międzynarodowego Stowarzyszenia Badań nad Rakiem Płuc (IASLC)
• Specjalizuje się w medycynie spersonalizowanej i immunoonkologii w leczeniu raka płuc